C/EBPβ expression is an independent predictor of overall survival in breast cancer patients by MHCII/CD4-dependent mechanism of metastasis formation

Oncogenesis

Volumn 3, Issue 11, 2014, Pages

  Kurzejamska, E ^a,b   Johansson, J ^a   Jirstrom K ^c   Prakash, V ^a,b   Ananthaseshan, S ^a   Boon, L ^d   Fuxe, J ^a   Religa, P ^a,b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b MEDICAL UNIVERSITY OF WARSAW   (Poland)

^c LUND UNIVERSITY   (Sweden)

^d BIOCEROS   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CCAAT ENHANCER BINDING PROTEIN BETA; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; SMALL INTERFERING RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CANCER GROWTH; CANCER INHIBITION; CANCER MORPHOLOGY; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; CD3+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD45+ T LYMPHOCYTE; CONTROLLED STUDY; CORRELATIONAL STUDY; DISEASE ASSOCIATION; FEMALE; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; INDEPENDENT VARIABLE; INFLAMMATION; LUNG METASTASIS; METASTASIS INHIBITION; METASTASIS POTENTIAL; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; OVERALL SURVIVAL; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE;

MURINAE; MUS; MUS MUSCULUS;

EID: 84927764023     PISSN: None     EISSN: 21579024     Source Type: Journal    
DOI: 10.1038/oncsis.2014.38     Document Type: Article

References (34)

1. Robinson GW, Johnson PF, Hennighausen L, Sterneck E. The C/EBPbeta transcription factor regulates epithelial cell proliferation and differentiation in the mammary gland. Genes Dev 1998; 12: 1907-1916.
2. Seagroves TN, Krnacik S, Raught B, Gay J, Burgess-Beusse B, Darlington GJ et al. C/EBP beta, but not C/EBP alpha, is essential for ductal morphogenesis, lobuloalveolar proliferation, and functional differentiation in the mouse mammary gland. Genes Dev 1998; 12: 1917-1928.
3. Zahnow CA. CCAAT/enhancer-binding protein beta: its role in breast cancer and associations with receptor tyrosine kinases. Expert Rev Mol Med 2009; 11: e12.
4. Johansson JBT, Kurzejamska E, Pang MF, Jansson M, Roswall P, Pietras K et al. MiR-155-mediated loss of C/EBP? shifts the TGF-? response from growth inhibition to epithelial-mesenchymal transition, invasion and metastasis in breast cancer. Oncogene 2013; 325614-5624.
5. Homma J, Yamanaka R, Yajima N, Tsuchiya N, Genkai N, Sano M et al. Increased expression of CCAAT/enhancer binding protein beta correlates with prognosis in glioma patients. Oncol Rep 2006; 15: 595-601.
6. Jundt F, Raetzel N, Muller C, Calkhoven CF, Kley K, Mathas S et al. A rapamycin derivative (everolimus) controls proliferation through down-regulation of truncated CCAAT enhancer binding protein beta and NF-kappa B activity in Hodgkin and anaplastic large cell lymphomas. Blood 2005; 106: 1801-1807.
7. Sebastian T, Johnson PF. Stop and go: anti-proliferative and mitogenic functions of the transcription factor C/EBPbeta. Cell Cycle 2006; 5: 953-957.
8. Gomis RR, Alarcon C, Nadal C, Van Poznak C, Massague J. C/EBPbeta at the core of the TGFbeta cytostatic response and its evasion in metastatic breast cancer cells. Cancer Cell 2006; 10: 203-214.
9. Zahnow CA, Cardiff RD, Laucirica R, Medina D, Rosen JM. A role for CCAAT/enhancer binding protein beta-liver-enriched inhibitory protein in mammary epithelial cell proliferation. Cancer Res 2001; 61: 261-269.
10. Milde-Langosch K, Loning T, Bamberger AM. Expression of the CCAAT/enhancerbinding proteins C/EBPalpha, C/EBPbeta and C/EBPdelta in breast cancer: correlations with clinicopathologic parameters and cell-cycle regulatory proteins. Breast Cancer Res Treat 2003; 79: 175-185.
11. Raught B, Gingras AC, James A, Medina D, Sonenberg N, Rosen JM. Expression of a translationally regulated, dominant-negative CCAAT/enhancer-binding protein beta isoform and up-regulation of the eukaryotic translation initiation factor 2alpha are correlated with neoplastic transformation of mammary epithelial cells. Cancer Res 1996; 56: 4382-4386.
12. Zahnow CA, Younes P, Laucirica R, Rosen JM. Overexpression of C/EBPbeta-LIP, a naturally occurring, dominant-negative transcription factor, in human breast cancer. J Natl Cancer Inst 1997; 89: 1887-1891.
13. Min Y, Ghose S, Boelte K, Li J, Yang L, Lin PC. C/EBP-delta regulates VEGF-C autocrine signaling in lymphangiogenesis and metastasis of lung cancer through HIF-1alpha. Oncogene 2011; 30: 4901-4909.
14. Marigo I, Bosio E, Solito S, Mesa C, Fernandez A, Dolcetti L et al. Tumor-induced tolerance and immune suppression depend on the C/EBPbeta transcription factor. Immunity 2010; 32: 790-802.
15. Sica A, Bronte V. Altered macrophage differentiation and immune dysfunction in tumor development. J Clin Invest 2007; 117: 1155-1166.
16. Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 2009; 9: 162-174.
17. Kusmartsev S, Nagaraj S, Gabrilovich DI. Tumor-Associated CD8+ T cell tolerance induced by bone marrow-derived immature myeloid cells. J Immunol 2005; 175: 4583-4592.
18. Hung K, Hayashi R, Lafond-Walker A, Lowenstein C, Pardoll D, Levitsky H. The central role of CD4(+) T cells in the antitumor immune response. J Exp Med 1998; 188: 2357-2368.
19. Dranoff G, Jaffee E, Lazenby A, Golumbek P, Levitsky H, Brose K et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA 1993; 90: 3539-3543.
20. Benevides L, Cardoso CR, Tiezzi DG, Marana HR, Andrade JM, Silva JS. Enrichment of regulatory T cells in invasive breast tumor correlates with the upregulation of IL-17A expression and invasiveness of the tumor. Eur J Immunol 2013; 43: 1518-1528.
21. Wang ZK, Yang B, Liu H, Hu Y, Yang JL, Wu LL et al. Regulatory T cells increase in breast cancer and in stage IV breast cancer. Cancer Immunol Immunother 2012; 61: 911-916.
22. Bohling SD, Allison KH. Immunosuppressive regulatory T cells are associated with aggressive breast cancer phenotypes: a potential therapeutic target. Mod Pathol 2008; 21: 1527-1532.
23. Tan W, Zhang WZ, Strasner A, Grivennikov S, Cheng JQ, Hoffman RM et al. Tumour-infiltrating regulatory T cells stimulate mammary cancer metastasis through RANKL-RANK signalling. Nature 2011; 470: 548-553.
24. Ng PKS, Tsui SKW, Lau CPY, Wong CH, Wong WHT, Huang L et al. CCAAT/enhancer binding protein beta is up-regulated in giant cell tumor of bone and regulates RANKL expression. J Cell Biochem 2010; 110: 438-446.
25. Muller A, Homey B, Soto H, Ge N, Catron D, Buchanan ME et al. Involvement of chemokine receptors in breast cancer metastasis. Nature 2001; 410: 50-56.
26. Kakinuma T, Hwang ST. Chemokines, chemokine receptors, and cancer metastasis. J Leukoc Biol 2006; 79: 639-651.
27. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002; 420: 860-867.
28. Yoshimura T, Howard OM, Ito T, Kuwabara M, Matsukawa A, Chen K et al. Monocyte chemoattractant protein-1/CCL2 produced by stromal cells promotes lung metastasis of 4T1 murine breast cancer cells. PLoS ONE 2013; 8: e58791.
29. Velasco-Velazquez M, Pestell RG. The CCL5/CCR5 axis promotes metastasis in basal breast cancer. Oncoimmunology 2013; 2: e23660.
30. Gery S, Tanosaki S, Bose S, Bose N, Vadgama J, Koeffler HP. Down-regulation and growth inhibitory role of C/EBPalpha in breast cancer. Clin Cancer Res 2005; 11: 3184-3190.
31. Yu X, Si J, Zhang Y, Dewille JW. CCAAT/enhancer binding protein-delta (C/EBP-delta) regulates cell growth, migration and differentiation. Cancer Cell Int 2010; 10: 48.
32. Radomska HS, Basseres DS, Zheng R, Zhang P, Dayaram T, Yamamoto Y et al. Block of C/EBP alpha function by phosphorylation in acute myeloid leukemia with FLT3 activating mutations. J Exp Med 2006; 203: 371-381.
33. Agrawal S, Hofmann WK, Tidow N, Ehrich M, van den Boom D, Koschmieder S et al. The C/EBP delta tumor suppressor is silenced by hypermethylation in acute myeloid leukemia. Blood 2007; 109: 3895-3905.
34. Svensson KJ, Christianson HC, Kucharzewska P, Fagerstrom V, Lundstedt L, Borgquist S et al. Chondroitin sulfate expression predicts poor outcome in breast cancer. Int J Oncol 2011; 39: 1421-1428.